CART22-65s and huCART19 for B-cell Acute Lymphoblastic Leukemia
This study is testing a new approach for children and young adults (up to 29 years old) with advanced B-cell Acute Lymphoblastic Leukemia (B-ALL) or B Lineage Lymphoblastic Lymphoma. It involves giving two types of CAR T cell therapy: CART22-65s and huCART19. These therapies use your own immune cells, engineered to find and fight cancer cells. Researchers want to see how safe and effective this combination is, especially for patients whose cancer has come back after previous treatments or didn't respond well to other cell therapies. The goal is to improve outcomes for patients whose cancer cells have specific markers (CD19 and/or CD22).
- Study design
- This interventional study plans to enroll 93 participants. It is not specified if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and the treatment's effectiveness will be checked for one year after receiving the therapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Co-administration of CART22-65s and huCART19 for B-ALL
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Regina Myers, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital of Philadelphia
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety of CART22-65s and huCART19 co-administration1 year
The safety of the administering CART22-65s and huCART19 will be measured by the monitoring the frequency and severity of adverse events in patients with advanced or refractory B-Cell Acute Lymphoblastic Leukemia or B Cell Lymphoblastic Lymphoma (B-LLy), including those previously treated with cell therapy.
- Efficacy of CART22-65s and huCART19 co-administration1 year
The efficacy of CART22-65s and huCART19 co-administration will be measured by the evaluating the overall response rate in patients with advanced or refractory B cell hematologic malignancies, including those previously treated with cell therapy.